Chester County News and Community Website
Immunome (NASDAQ: IMNM), headquartered in Exton, PA, is a biopharmaceutical company utilizing a proprietary human memory B cell platform to discover and develop first-in-class antibody therapeutics designed to change the way diseases are currently being treated. Immunome’s proprietary discovery platform identifies novel therapeutic antibodies and their targets by leveraging highly educated components of the immune system, memory B cells, from patients whose bodies have learned to fight off their disease. For more information about the company, visit http://immunome.com.
EXTON, PA — Immunome, Inc. (Nasdaq: IMNM) announced that Purnanand Sarma, Ph.D., Immunome’s President and CEO, will present at the Cantor Global Healthcare Conference on Wednesday, September 29, 2021, at …
Read More EXTON, PA — Immunome, Inc. (Nasdaq: IMNM) recently reported financial results for the second quarter ended June 30, 2021, and provided a corporate update.
Read More EXTON, PA — Immunome, Inc. (Nasdaq: IMNM) announced that its three-antibody cocktail (IMM-BCP-01) has demonstrated potent neutralizing activity against the SARS-CoV-2 Delta variant in pre-clinical pseudovirus testing. Furthermore, IMM-BCP-01 showed …
Read More EXTON, PA — Immunome, Inc. (Nasdaq: IMNM) announced that Purnanand Sarma, Ph.D., Immunome’s President and CEO, will present at the Ladenburg Thalmann 2021 Healthcare Conference on Tuesday, July 13, 2021, …
Read More EXTON, PA — Immunome, Inc. (Nasdaq: IMNM), a biopharmaceutical company that utilizes its human memory B cell discovery engine platform to discover and develop first-in-class antibody therapeutics, this week announced …
Read More EXTON, PA — Immunome, Inc. (Nasdaq: IMNM) announced that Purnanand Sarma, Ph.D., President and CEO of Immunome, will present at the Jefferies Virtual Healthcare Conference on Friday, June 4, 2021, …
Read More EXTON, PA — Immunome, Inc. (Nasdaq: IMNM), a biopharmaceutical company that utilizes its human memory B cell discovery engine platform to discover and develop first-in-class antibody therapeutics, announced a $4.3 …
Read More EXTON, PA — Immunome, Inc. (Nasdaq: IMNM), a biopharmaceutical company that utilizes its human memory B cell discovery engine platform to discover and develop first-in-class antibody therapeutics, reported financial results …
Read More EXTON, PA — Immunome, Inc. (Nasdaq: IMNM), a biopharmaceutical company that utilizes its human memory B cell discovery engine platform to discover and develop first-in-class antibody therapeutics, this week announced …
Read More EXTON, PA — Immunome, Inc. (Nasdaq: IMNM), a biopharmaceutical company that utilizes its human memory B cell discovery engine platform to discover and develop first-in-class antibody therapeutics, this week announced …
Read More